With the immunohistochemical specimens of GC and treatment information, it was found that high expression of PAK6 leads to poor prognosis in the patients treated with oxaliplatin after surgery but not those threated through surgery only or capecitabine (an oral pro drug of 5-fluorouracil) after surgery. This evidence concerns the gene PAK6 and gastric cancer.